Login / Signup

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome.

Shang Yu WangChiao-En WuChun-Chi LaiJen-Shi ChenChun-Yi TsaiChi-Tung ChengTa-Sen YehChun-Nan Yeh
Published in: Cancers (2019)
Our analysis supports treating GIST patients with neoadjuvant imatinib, which demonstrated favorable long-term results of combined therapy. However, careful monitoring of complications is necessary. The optimal duration of neoadjuvant imatinib use before surgical intervention is, on average, 6.1 months.
Keyphrases